ClinicalTrials.Veeva

Menu

Study of Carrageenan's Effect on Insulin Resistance in Humans

U

University Hospital Tuebingen

Status

Completed

Conditions

Insulin Resistance
Diabetes Mellitus, Type 2

Treatments

Dietary Supplement: Carrageenan
Dietary Supplement: Placebo

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of this study is to determine whether the ingestion of the common food additive carrageenan contributes to insulin resistance and thus to the pathogenesis of type 2 diabetes in humans.

Enrollment

20 patients

Sex

Male

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • body mass index (BMI) 18.5 - 29.9 kg/m²

Exclusion criteria

  • any chronic illness
  • any ongoing medication
  • known infections
  • known liver disease
  • known renal insufficiency
  • alcohol consumption over 30 g/d
  • shift work

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

20 participants in 2 patient groups

Group A
Other group
Description:
1. Placebo intervention 2. Assessment block (3 days) 3. Washout-phase of 21-35 days 4. Carrageenan intervention 5. Assessment block (3 days)
Treatment:
Dietary Supplement: Placebo
Dietary Supplement: Carrageenan
Group B
Other group
Description:
1. Carrageenan intervention 2. Assessment block (3 days) 3. Washout-phase of 21-35 days 4. Placebo intervention 5. Assessment block (3 days)
Treatment:
Dietary Supplement: Placebo
Dietary Supplement: Carrageenan

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems